Hrt Financial LP Puma Biotechnology, Inc. Transaction History

Hrt Financial LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$4.29 - $7.4 $545,820 - $941,509	127,231 New	127,231 $674,000
Q4 2022 Feb 10, 2023	BUY	$2.12 - $5.08 $64,481 - $154,513	30,416 New	30,416 $128,000
Q2 2022 Aug 12, 2022	BUY	$1.64 - $3.3 $29,577 - $59,515	18,035 New	18,035 $51,000
Q1 2022 May 16, 2022	SELL	$2.13 - $3.24 $170,564 - $259,449	-80,077 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $57,096 - $131,823	-20,034 Reduced 20.01%	80,077 $243,000
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $66,266 - $93,853	9,995 Added 11.09%	100,111 $701,000
Q2 2021 Aug 16, 2021	BUY	$8.98 - $11.6 $451,846 - $583,677	50,317 Added 126.43%	90,116 $827,000
Q1 2021 May 17, 2021	BUY	$9.38 - $13.63 $39,986 - $58,104	4,263 Added 12.0%	39,799 $386,000
Q4 2020 Feb 16, 2021	SELL	$7.78 - $12.13 $113,992 - $177,728	-14,652 Reduced 29.19%	35,536 $364,000
Q3 2020 Nov 13, 2020	BUY	$9.5 - $11.14 $476,786 - $559,094	50,188 New	50,188 $506,000

30.5M

73.5K

18.5K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $116M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.